IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for ...

“Sexuality and intimacy are important aspects of quality of life and may also reduce some of the psychosocial distress ...

One near-term rival is Johnson & Johnson's FcRn inhibitor nipocalimab, which started a phase 3 programme last December.

Gepotidacin was approved by the FDA earlier this year, under the Blujepa brand, as the first oral antibiotic to offer a new ...

Haematological cancers are a recognised potential side effect with Skysona and were already mentioned in a boxed warning on ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

One major and often overlooked factor contributing to this imbalance is the way health outcomes are measured in clinical ...